Literature DB >> 496054

Comparative pharmacokinetics of d-tubocurarine and metocurine in man.

D K Meijer, J G Weitering, G A Vermeer, A H Scaf.   

Abstract

To compare the pharmacokinetics of d-tubocurarine and metocurine in man, concentrations of 3H-d-tubocurarine and 14C-metocurine (0,0,N-trimethyl-tubocurarine) in plasma, urine and bile were determined after intravenous administration of d-tubocurarine, 0.15 mg/kg (five patients), and metocurine, 0.05 mg/kg (five patients), in patients anesthetized with thiopental and nitrous oxide for cholecystectomy. Plasma disappearances of both drugs were triexponential, with mean terminal half-lives of 346 and 217 min for d-tubocurarine and metocurine, respectively. By ion-pair thin-layer chromatography, no metabolite of either compound was found in urine or bile. Renal excretions 48 hours after injection ranged from 46 to 95 per cent of the dose for d-tubocurarine and from 46 to 58 per cent for metocurine. Mean total-body clearances were 56 and 96 ml/min for d-tubocurarine and metocurine, respectively. Biliary elimination of d-tubocurarine was greater than that of metocurine: within 48 hours 11.8 and 2.1 per cent of the doses were excreted in bile, respectively. The observed differences in total-body clearances and volumes of distribution (V1) may be partly explained by greater protein binding of d-tubocurarine. The results indicate that biliary excretion is an alternative route of elimination for d-tubocurarine only. Also, d-tubocurarine is less dependent on renal excretion for its elimination, and probably is preferable to metocurine for use in patients with renal failure.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 496054     DOI: 10.1097/00000542-197911000-00007

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  9 in total

Review 1.  Clinical pharmacokinetics of neuromuscular blocking drugs.

Authors:  S Agoston; R H Vandenbrom; J M Wierda
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

Review 2.  Carrier-mediated transport in the hepatic distribution and elimination of drugs, with special reference to the category of organic cations.

Authors:  D K Meijer; W E Mol; M Müller; G Kurz
Journal:  J Pharmacokinet Biopharm       Date:  1990-02

Review 3.  Pharmacokinetics in intravenous anaesthetic practice.

Authors:  P Duvaldestin
Journal:  Clin Pharmacokinet       Date:  1981 Jan-Feb       Impact factor: 6.447

Review 4.  Which drug--steroid or benzylisoquinolinium?

Authors:  B J Pollard
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

5.  Model determination for use in automated control of drug dosages: application to d-tubocurarine.

Authors:  H S Bradlow; B G Sherlock; R E Thornington; E S Solomon
Journal:  Med Biol Eng Comput       Date:  1983-03       Impact factor: 2.602

6.  Pharmacokinetics of biliary excretion in man V. Dibromosulfophthalein.

Authors:  D K Meijer; J G Weitering; G A Vermeer
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 7.  Clinical pharmacokinetics of the non-depolarising muscle relaxants.

Authors:  M I Ramzan; A A Somogyi; J S Walker; C A Shanks; E J Triggs
Journal:  Clin Pharmacokinet       Date:  1981 Jan-Feb       Impact factor: 6.447

Review 8.  Selecting neuromuscular-blocking drugs for elderly patients.

Authors:  Tristan M Cope; Jennifer M Hunter
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

9.  Pharmacokinetics and quantitative characterization of cefotiam excretion after intravenous administration to patients after cholecystectomy.

Authors:  D Terziivanov; Z Gerova; V Vlahov; A Merdzhanov; D Damjanov
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.